Many medically minded researchers are in hot pursuit of designs that will allow drug-carrying nanoparticles to navigate tissues and the interiors of cells, but engineers have discovered that these particles have another hurdle to overcome: escaping the bloodstream.
Teva Pharmaceutical Industries Ltd.'s fourth-quarter earnings sank 37%, as generic competition from other companies hurt revenue for one of the world's biggest generic drugmakers. The Israeli company said its revenue from the United States fell 14% in the quarter to $2.62 billion.
Bausch + Lomb has initiated its Phase 3 clinical program of latanoprostene bunod for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. This program includes two separate randomized, multicenter, double-masked, parallel-group clinical studies.
Eli Lilly and Company will discontinue the Phase 3 rheumatoid arthritis program for tabalumab, an anti-B cell activating factor monoclonal antibody, due to lack of efficacy. The tabalumab Phase 3 program for systemic lupus erythematosus, ILLUMINATE, is ongoing and will continue as planned.
Neurologists say minimally invasive delivery of the drug tPA directly into potentially lethal blood clots in the brain helped more patients function independently a year after suffering an intracerebral hemorrhage, a deadly and debilitating form of stroke. Rates of functional recovery with the active tPA treatment far surpassed those achieved with standard supportive therapy.
Researchers have discovered the first U.S. cases of whooping cough caused by a germ that may be resistant to the vaccine. Health officials are looking into whether cases like the dozen found in Philadelphia might be one reason the nation just had its worst year for whooping cough in six decades.
A team of researchers at Weill Cornell Medical College has discovered that amyloid peptides are harmful to the blood vessels that supply the brain with blood in Alzheimer's disease—helping accelerate cognitive decline by limiting oxygen-rich blood and nutrients.
Three clinical trials that seek to find more effective treatments for influenza are enrolling volunteers with influenza at the National Institutes of Health’s Clinical Center in Bethesda, Md., and at several dozen other domestic and international sites.
Metabolic imbalance, such as diabetes and obesity, is often caused by elevated carbohydrate intake, which can lead to over-activating a molecule called C-terminal binding protein (CtBP). This over-activation, in turn, can increase the risk of breast cancer.
Scientists have found that the microRNA miR-7 is a metastasis suppressor in cancer stem-like cells. When the research team increased expression of miR-7 in cancer stem-like cells from metastatic human breast cancer cell lines, it suppressed their metastatic properties.
Cosmetic drug and device maker Allergan Inc. said its fourth-quarter profit increased more than 16% on higher sales of Botox and eye care products. Net income for the period was $324.2 million, up from $280 million, in the last quarter of 2011.
Idenix Pharmaceuticals Inc. is ending development of two hepatitis C drugs after regulators told the biopharmaceutical company the drugs would remain on clinical hold. The drugs, IDX184 and IDX19368, are both nucleotide inhibitors that prevent the virus from making copies of itself.
Federal regulators say approval of the first generic version of cancer drug Doxil will help resolve a lingering shortage triggered by manufacturing deficiencies. The shortage of the Johnson & Johnson injectable medication, made under contract by Ben Venue Laboratories, has continued on and off for a few years.
Drugmaker Medicines Co. is entering an alliance with Alnylam Pharmaceuticals Inc. to help develop the biopharmaceutical company's RNA interference drugs that could potentially help lower cholesterol. Alnylam's drugs use RNA interference, or RNAi, technology.
An analyst has downgraded Merck & Co. from a "Buy" to "Sell." Morgan Stanley & Co. analyst David Risinger, in a note to investors, cites concerns that upcoming study results could hurt sales of a blockbuster cholesterol medicine, plus an unexpected delay on a crucial experimental drug.